Skip to content

Granulocyte colony-stimulating factor-mediated neuroprotection for acute spinal cord injury

Granulocyte colony-stimulating factor-mediated neuroprotection for acute spinal cord injury - G-CSF therapy for spinal cord injury

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001079
Enrollment
10
Registered
2008-04-01
Start date
2008-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute spinal cord injury

Interventions

administration of granulocyte colony-stimulating factor

Sponsors

Chiba University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Acute spinal cord injury patients (within 8 hours after the injury). The patient who does not conflict with exclusion criteria. The patient who has sufficient understanding in participation of an exam, and the patient by whom the document consent by the free intention of the person himself/herself was got.

Exclusion criteria

Exclusion criteria: Allergy for G-CSF. A patient with the past of a hematopoietic system malignant disease, any malignant disease within 5 years, angina, myocardial infarction, thrombosis, splenpmegary, consciousness disorder or pregnancy. A patient with the past which has concurred with the diseases of the nervous system which can have on neurological-symptoms evaluations, such as cerebral infarction. In addition, the patient whom the examination responsibility (assignment) doctor judged to be unsuitable as a subject.

Design outcomes

Primary

MeasureTime frame
To clarify the safety of granulocyte colony-stimulating factor for acute spinal cord injury

Secondary

MeasureTime frame
degree of sensory or motor paralysis, functional impairment coused by the paralysis, MRI imaging of injured spinal cord

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026